The initial experience of electronic brachytherapy for the treatment of non-melanoma skin cancer by Bhatnagar, Ajay & Loper, Alphonse
RESEARCH Open Access
The initial experience of electronic brachytherapy
for the treatment of non-melanoma skin cancer
Ajay Bhatnagar
1,2*, Alphonse Loper
2
Abstract
Background: Millions of people are diagnosed with non-melanoma skin cancers (NMSC) worldwide each year.
While surgical approaches are the standard treatment, some patients are appropriate candidates for radiation
therapy for NMSC. High dose rate (HDR) brachytherapy using surface applicators has shown efficacy in the
treatment of NMSC and shortens the radiation treatment schedule by using a condensed hypofractionated
approach. An electronic brachytherapy (EBT) system permits treatment of NMSC without the use of a radioactive
isotope.
Methods: Data were collected retrospectively from patients treated from July 2009 through March 2010.
Pre-treatment biopsy was performed to confirm a malignant cutaneous diagnosis. A CT scan was performed to
assess lesion depth for treatment planning, and an appropriate size of surface applicator was selected to provide
an acceptable margin. An HDR EBT system delivered a dose of 40.0 Gy in eight fractions twice weekly with 48
hours between fractions, prescribed to a depth of 3-7 mm. Treatment feasibility, acute safety, efficacy outcomes,
and cosmetic results were assessed.
Results: Thirty-seven patients (mean age 72.5 years) with 44 cutaneous malignancies were treated. Of 44 lesions
treated, 39 (89%) were T1, 1 (2%) Tis, 1 (2%) T2, and 3 (7%) lesions were recurrent. Lesion locations included the
nose for 16 lesions (36.4%), ear 5 (11%), scalp 5 (11%), face 14 (32%), and an extremity for 4 (9%). Median follow-up
was 4.1 months. No severe toxicities occurred. Cosmesis ratings were good to excellent for 100% of the lesions at
follow-up.
Conclusions: The early outcomes of EBT for the treatment of NMSC appear to show acceptable acute safety and
favorable cosmetic outcomes. Using a hypofractionated approach, EBT provides a convenient treatment schedule.
Background
The incidence of both non-melanoma and melanoma
skin cancers has been increasing over the past decade.
An estimated 2 to 3 million non-melanoma skin cancers
(NMSC) occur in the U.S. each year, [1] which is greater
than the estimated number of new cases of all other
types of cancer combined [2]. If the rate of occurrence
of NMSC per capita is similar in Europe, then approxi-
mately 4 million cases of NMSC could be expected in
the European Union’s population of 501 million people
e a c hy e a r .I nt h eU . K .a l o n e ,8 4 , 5 0 0c a s e so fN M S C
were registered in 2007, and this number was known to
be an underestimate of the number of diagnosed cases
[3]. According to the American Academy of Dermatol-
ogy, 80% of NMSC lesions in the U.S. are basal cell car-
cinomas (BCC), and 16% are categorized as squamous
cell carcinoma (SCC) [4].
A variety of modalities for the treatment of BCC and
SCC are available, including surgery, radiation therapy
and topical agents. Surgical options, including curettage
with electrodessication, Mohs micrographic surgery, and
surgical excision, are the most frequently used treat-
ments, providing a high control rate and satisfactory
cosmetic results [5-7]. However, some patients are not
suitable candidates for surgery due to age or general
health, and some cases of NMSC may not be optimally
treated with surgery due to the potential for disfigure-
ment. Aggressive cases of SCC may respond best to a
combination of surgery and post-surgical adjuvant ther-
apy [8]. Radiation therapy, including external beam and
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post-surgical adjuvant therapy for NMSC. External
beam radiation modalities have included superficial
x-rays (45-100 kV), orthovoltage x-rays (100-250 kV),
megavoltage photons, and electron beam radiation. Pub-
lished studies report local control ranging from 87-100%
at two to five years with excellent to good cosmetic out-
comes reported in the absence of grade 4 toxicities
[9-14]. Dose fractionation schemes for external beam
radiation therapy are based on the size and location of
the lesion and can take up to seven weeks of daily treat-
ments for a 70 Gy prescription dose to be delivered in
35 fractions [9-13]. High Dose Rate (HDR) brachyther-
apy using skin surface applicators or surface molds can
reduce the number of treatments and the duration of
the treatment schedule. Kohler-Brock, et al., reported
their 10-year experience with 520 patients with skin
lesions mainly comprising SCC and BCC treated with
standardized surface applicators and a remote afterload-
ing HDR system. The dose per fraction ranged from
5-10 Gy delivered once to twice per week with a total
dose ranging from 30-40 Gy. The recurrence rate was
8%, and there were no observed severe late radiation
reactions [15]. Guix, et al., published their series of 136
patients with BCC or SCC of the face treated with sur-
face molds and HDR brachytherapy using a radioisotope
source (Ir-192) and showed a 5-year local control rate
of 98% with no severe early or late complications
detected [16].
Electronic brachytherapy (EBT) is the administration
of HDR brachytherapy without the use of a radioactive
isotope and with minimal shielding requirements due to
the low energies utilized with this system. EBT treat-
ments are delivered using the Axxent® System controller,
source and surface applicators (Xoft Inc., Sunnyvale,
CA), which have been cleared by the United States Food
and Drug Administration to deliver HDR X-ray radia-
tion for brachytherapy. The EBT skin surface applicator
weighs less than 2 pounds and appears similar to the
Leipzig applicator used with HDR Iridium-192 (Ir-192)
brachytherapy (Figure 1). Dosimetric analyses have been
performed revealing similar depth dose profiles for these
two surface applicators (Figure 2) [17-19]. However,
data output for the beam profile measurements show
superior beam flatness with reduced penumbra for the
EBT surface applicator (Figure 3) [17-20].
The purpose of this manuscript is to report the initial
experience, feasibility, and clinical outcomes of EBT
using the Axxent System and surface applicators for the
treatment of NMSC.
Methods
All patients treated with EBT for NMSC at Cancer
Treatment Services - Arizona from July 2009 through
March 2010 were included in this study. This retrospec-
tive study was approved by Integriew Ethical Review
Board. Data were collected retrospectively on a case
report form from the medical records. Pre-treatment
biopsy for NMSC had been performed on all patients to
confirm the diagnosis prior to treatment. A series of
digital photographs of the initial lesion on each patient
was obtained.
Simulation
Customized immobilization using a thermoplastic mask
(Civco, Orange City, IA) for facial lesions and Vac-Lok™-
bags (Civco, Orange City, IA) for extremity lesions were
used to immobilize and locate the area to be treated
prior to administration of each fraction. The customized
immobilization ensured constant and complete surface
contact between the surface applicator and the skin
lesion for the duration of the treatment. All patients
Figure 1 EBT Surface Applicators for Use with the Axxent®
System.
Figure 2 Depth Dose Comparison of HDR EBT with HDR
192Iridium.
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assess skin depth. A digital photo, illustrating the
method of immobilization of the treatment area and a
simulation of the set-up of the system prior to the first
fraction, was taken.
A typical treatment area definition begins with an
assessment of the visible surface lesion, known as the
gross tumor volume (GTV). An additional margin to
account for measurement uncertainty, profile edge
effect, and uncertainty in applicator placement was
added; this constitutes the planning target volume
(PTV). An applicator diameter that was large enough to
encompass the entire PTV was chosen.
Treatment Planning
The objective of the treatment planning process for
EBT using the surface applicators is to calculate a
dwell time to deliver the prescribed dose at a specified
depth. The process for EBT surface application treat-
ments follows a similar approach as traditional Ir-192
HDR brachytherapy using the Leipzig applicators. In
both modalities, a prescription depth and dose are
chosen, an applicator size is selected, and the patient is
treated for a dwell time. The key distinction between
the two modalities is the calibration and calculations
associated with the EBT 50 kV source versus the Ir-
192 source.
After the applicator size is selected, a single dwell
position is used to deliver the prescribed dose (Dpre-
scribed) to the prescription depth. The nominal dwell
time (tNominal), the calculated time to deliver the dose to
the single dwell position, is calculated using the follow-
ing factors: (Ďnominal)i nG y / m i n ,b a s e do nt h eA A P M
Task Group 61 report, [21] the percentage depth dose
(PDD) and the prescribed dose (Dprescribed). When fol-
lowing the TG-61 protocol, the source and surface
applicator are calibrated as a set, and all measurements
are dependent on the actual air kerma strength of the
source used (AKSActual) and the nominal air kerma
strength (where AKSNominal = 110,000 U). The actual
dose rate (ĎActual) must be converted to a nominal dose
rate (ĎNominal) as shown below.
D D AKS AKS Nominal Actual Nominal Actual
 = */
The nominal dose rate at the prescription depth (ĎRx)
is related to the PDD as shown below.
DD P D D Rx Nominal  = *
The nominal dwell time (tNominal) is then computed
from ĎRx and the prescribed dose (Dprescribed)a ss h o w n
below.
tDD Nominal prescribed Rx = / 
The actual treatment time (tactual)i sc a l c u l a t e dp r i o r
to each treatment with measurement of the AKSActual
using real time temperature-pressure correction as
shown below.
t t AKS AKS actual nominal Nominal Actual = () /
When customized shieldingi su s e dt oo p t i m i z et h e
dose to the PTV, a layer of high-density material, such
as 1 mm lead or any commercially approved shielding
can be used. The cut-out correction factors can be mea-
sured in the phantom as shown below.
OF
MM
CutoutCone A
ConeA uncollimated ConeA collimated
=
()( ) /
The Nominal Dose Rate with the cutout should be
adjusted by the Cone and Cut-out corrections, as shown
below, so that the tNominal can be calculated.
D
DO F O F
Nominal  cutout
Nominal  reference CutoutCone A Co


,
, **
=
n neA
Treatment Delivery
T h eE B Ts y s t e mi n c l u d e sam i n iature, electronic, high
dose rate, low energy X-ray tube integrated into a flexible,
multi-lumen catheter. This source produces X-rays of 50
keV maximum energy at the tip of the catheter. The EBT
system also includes a mobile controller that contains the
user interface and provides power to the X-ray source.
Additional details on the EBT system are provided by
Mehta, et al. [22] The EBT system with surface applicators
was utilized to deliver a dose of 40.0 Gy in 8 fractions, 5
Figure 3 EBT Source Beam Profile.
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weekly with a minimum of a 48-hour interval between
fractions. The prescription dose depth ranged from 3-7
mm based on the lesion depth. The PTV consisted of the
lesion plus an acceptable margin. The margins ranged
from 2 to 5 mm depending on treatment location. Initially,
the 35 mm surface applicator was available prior to the
other sizes, and commercially available cutout shielding
was used under the surface applicator. Once all four appli-
cator sizes were available, all four sizes were used.
All patients were treated outside of a linear accelerator
vault in the CT simulator room. A flexible shield was
placed over the applicator to minimize radiation expo-
sure. Our site’s standard of care was to provide a petro-
latum ointment such as Eucerin® Aquaphor® ointment
(Beiersdorf, Inc, Wilton, CT) to be applied to the treat-
ment area three to four times per day during the dura-
tion of the radiation therapy treatments. Once the
treatments were completed, patients were advised
t oa p p l ya na l o ev e r ag e lt ot h et r e a t m e n ta r e at h r o u g h
1-month of follow up.
Endpoints
Endpoints included treatment feasibility, acute safety
outcomes, cosmetic results, and short-term efficacy.
Treatment feasibility was defined as the successful
delivery of the prescribed dose following the intended
treatment schedule. Adverse events were collected dur-
ing treatment and follow-up visits. Adverse events
were categorized and graded according to the Com-
mon Terminology Criteria for Adverse Events
(CTCAE) version 3 manual [23]. Efficacy was based on
the rate of local recurrence. Cosmesis was rated as
excellent, good, fair or poor using a standardized
cosmesis scale [24]. Excellent was defined as no
changes to slight atrophy or pigment change or slight
hair loss or no changes to slight induration or loss of
subcutaneous fat. Good was defined as patch atrophy,
moderate telangiectasia, total hair loss; moderate fibro-
sis but asymptomatic, slight field contracture with less
than 10% linear reduction. Fair was defined as marked
atrophy, gross telangiectasia; severe induration or loss
of subcutaneous tissue; field contracture greater than
10% linear measurement. Poor was defined as ulcera-
tion or necrosis [24].
Results
Patient Demographics
Thirty-seven patients with 44 cutaneous malignancies
were treated with a HDR electronic brachytherapy
system between July 2009 and March 2010. Table 1
represents the patient demographics for this study.
Twenty-five (56.8%) lesions were BCC, 17 (38.6%) were
SCC, one (2.3%) was Merkle Cell, and one (2.3%) was
cutaneous T-cell lymphoma. The mean age of the
patients was 72.5 years and ranged from 49 to 89 years.
Thirty-nine of the 44 lesions (89%) were T1, one lesion
(2.3%) was Tis, one lesion (2.3%) was T2, and three
lesions were recurrences (6.8%) after prior surgical
resection. Ninety-five percent of patients were Caucasian
non-Hispanic, and 5% were Hispanic. Seventy-three per-
cent of the patients were male.
All patients and all lesions underwent successful com-
pletion of treatment with the prescribed dose according
to the treatment plan. All 44 lesions were treated with
40.0 Gy in eight fractions of 5.0 Gy each. Of the 44
lesions treated, 16 (36.4%) lesions were located on the
nose, including the nasal ala, the nasal tip, and nostril.
Five lesions (11%) were on the ear, which consisted of
t h ep i n n a ,a n t h e l i x ,a n de a rl o b e .F i v el e s i o n s( 1 1 % )
were located on the scalp, which included the top of the
head and the post-auricular area. Fourteen lesions (32%)
were on the face and included lesions on the forehead,
cheek, temple, pre-auricular area, nasolabial fold. Four
lesions (9%) were located on an extremity (Table 1).
The applicator sizes included 10 mm, used to treat
35% of the lesions, 20 mm, used to treat 25%, 35 mm,
used to treat 43% of the lesions, and 50 mm, used for
one patient (2%). The lesion sizes ranged from <1 cm to
5 cm as summarized in Table 2. Commercially available
cutout shielding was used under the surface applicator
Table 1 Demographics at Baseline
Total
Histology N Percent
Basal Cell 25 56.8%
Squamous cell 17 38.6%
Merckle Cell 1 2.3%
T-Cell Lymphoma 1 2.3%
Tumor Stage N Percent
Tis 1 2.3%
T1 39 88.6%
T2 1 2.3%
Recurrence 3 6.8%
Ethnicity N Percent
Caucasian/Non-Hispanic 35 94.6%
Hispanic 2 5.4%
Gender N Percent
Male 27 73.0%
Female 10 27.0%
Lesion Locations N %
Scalp 5 11.4%
Face 14 31.8%
Nose 16 36.4%
Extremity 4 9.1%
Ear 5 11.4%
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to the skin beyond the PTV of 13 (29%) lesions. Six of
13 lesions were less than 1 cm in diameter, and 7 of the
lesions were 1-2 cm in diameter. The prescription depth
varied with the lesion depth and was 5 mm beyond the
skin surface in 34 of the lesions and 3 mm depth in 9 of
the lesions. One patient with a cutaneous T-cell lym-
phoma plaque had a deep lesion based on CT imaging
which necessitated the prescription dose depth to be 7
mm for the first four fractions and 5 mm for the final
four fractions as the tumor size began to decrease. The
patients who underwent treatment with a prescription
dose depth of 3 mm had lesions on the face in 6, the
nose in 1, the ear in 1, and the scalp in 1. The mean
treatment time was 6.8 minutes with a range from 4.7
to 13.8 minutes. The treatment times by applicator size
and prescription dose depth are listed in Table 3.
Patients were followed for a median of 4.1 months
(range 1-9 months). There have been no recurrences to
date. Cosmetic outcomes were assessed as excellent,
good, fair or poor according to Cox, et al., at each fol-
low-up visit [24]. All patients had an excellent or good
cosmetic outcome at each follow-up visit. At 1-month
of follow up, 90% of patients had excellent cosmesis,
and 10% had good cosmesis. At 3-months of follow up,
95% of the 19 evaluable patients had excellent cosmesis,
and 5% had good cosmesis. An example of BCC treat-
ment resulting in an excellent cosmetic outcome at 6
months post-radiation therapy is shown in Figure 4.
Adverse Events
All adverse events that occurred were CTCAE grade 1 or
grade 2 regardless of prescription dose depth, which var-
ied with lesion depth [23]. The prescription dose was 40
Gy for all patients. The patients who experienced grade 2
adverse events are listed in Table 4. For the patients who
were treated with 40 Gy prescribed to a depth of 3 mm,
all adverse events were grade 1. Seven of 8 (86%) adverse
events are resolved, and one adverse event, erythema
grade 1, was ongoing at 1-month of follow up and will
undergo additional follow up. For the patients who
underwent treatment of 40 Gy prescribed to a depth of
5 mm, 12 patients experienced grade 2 rash-dermatitis
associated with radiation. All events have resolved except
one, which improved to grade 1 at the 3-month follow-
up visit and was ongoing at 6 months of follow up. One
patient was treated for cutaneous T-cell lymphoma at a
prescription depth of 7 mm. This patient experienced
rash-dermatitis associated with radiation reported at frac-
tion 7, and the adverse event was resolved at the 2-month
follow-up visit. (Figure 5).
Discussion
The incidence of skin cancer is rapidly rising, and the
treatment approach must be individualized based on
specific risk factors and patient characteristics in order
to achieve the most acceptable cosmetic and functional
outcome. For those patients where surgical resection is
not an ideal option or for those patients not interested
in surgery, radiation therapy is a viable option. However,
the traditional dose fractionation schemes lasting 5-7
weeks of daily radiation could result in this modality as
a less desirable option for skin cancer patients. HDR
brachytherapy offers a convenient treatment schedule
for patients and is associated with excellent outcomes
[15,16].
This report represents the initial experience using an
electronic source for HDR brachytherapy with surface
applicators for the treatment of NMSC. All patients
received a hypofractionated course of EBT comparable
to published treatment schedules for traditional HDR
brachytherapy with a radioisotope source. The early
results with EBT show similar outcomes to that with
Table 2 Applicator Sizes and Corresponding Lesion Size
Range
Applicator
Size
Lesion
Size Range
Number
of Lesions
Percent Of
Total Lesions
10 mm < 1 cm 13 29.5%
20 mm 1 cm 2 4.5%
> 1 cm and ≤ 2 cm 9 20.5%
35 mm
1 ≤ 1 cm 6 13.6%
> 1 cm and ≤ 2 cm 12 27.3%
> 2 cm and ≤ 3 cm 1 2.3%
50 mm 5 cm 1 2.3%
mm = millimetre; cm = centimetre.
1Cut-out shielding was used with the 35 mm applicator to treat 6 lesions ≤ 1
cm and 7 lesions > 1 cm and ≤ 2c m .
Table 3 Treatment Times in Minutes By Applicator Size and Prescription Dose Depth
10 mm Applicator 20 mm Applicator 35 mm Applicator 50 mm Applicator
Prescription Dose Depth 3 mm 5 mm 3 mm 5 mm 5 mm 7 mm
No. of Lesions 6738 1 9 1
Treatment Time
Mean 4.8 6.5 5.9 7.7 6.8 13.8
Min 4.7 5.3 5.6 7.0 5.8 13.8
Max 5.2 6.8 6.1 7.9 7.7 13.8
mm = millimetre; min = minimum; max = maximum.
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patients with severe (Grade 3 or higher) toxicities. Addi-
tionally, all patients had a decline in or resolution of
skin toxicities after 1 month of follow up. There have
been no recurrences as of this publication with a mean
follow up of 4.1 months (range 1-9 months).
Long-term control rates for NMSC treated with exter-
nal beam radiation therapy, including superficial x-rays
(45-100 kV), orthovoltage x-rays (100-250 kV), megavol-
tage photons, and electron beam radiation, range from
87% to 100% after a follow up of 2 to 5 years [9-14].
High dose rate brachytherapy with Ir-192 for NMSC has
shown control rates of 92% to 98% after 5 to 10 years of
follow up [15,16]. Other nonsurgical interventions for
BCC and SCC include photodynamic therapy, laser ther-
apy and a combination of the two. Photodynamic ther-
apy for superficial BCC has a tumor-free rate of 91.2%
to 94.8%, which increases to 99.0% when combined with
erbium:yttrium aluminium garnet (Er:YAG) laser after a
follow up of 3 months to 1 year [25,26]. Neodymium
(Nd) and Nd:YAG lasers have been used in patients
with facial NMSC; recurrence rates were 1.8% and 2.5%
in BCC treated with pulsed Nd or Nd:YAG laser therapy
and 4.4% in SCC treated with pulsed Nd laser after a
follow up of 3 months to 5 years [27].
The dosimetric results for electronic brachytherapy and
Ir-192 brachytherapy using surface applicators revealed
similar depth dose profiles, [17-19] which could possibly
explain the similar outcomes thus far. Additional follow-
up data on EBT with surface applicators is needed in
order to compare EBT with the long-term efficacy data
Figure 4 EBT Treatment of Basal Cell Carcinoma. Photo at pretreatment (top left), prior to fraction 7 of 8 (top right), at one-month follow up
(bottom left), and at six months of follow up (bottom right).
Table 4 Adverse Events with CTC AE Grade 2 Rash
Dermatitis Associated With Radiation
1,2
Subject Onset Improved to
Grade 1
Resolved
1 Fraction
8
1 month 3 month
2 Fraction
5
Fraction 8 1 month
3 Fraction
4
1 month 3 month
4 Fraction
7
———————————— 1 month
5 Fraction
4
1 month 6 month
6 1 month 3 month Ongoing at 6
months
7, 8, 9,
10
Fraction
8
—————————————— 1 month
11, 12 Fraction
8
—————————————— 4 month
1 All cases of rash dermatitis associated with radiation were assessed as
CTCAE Grade 2, and all prescriptions were to a dose depth of 5 mm.
2 One case of rash dermatitis grade 2 occurred in the patient with cutaneous
T-cell lymphoma. Prescription depth was 7 mm. The rash dermatitis improved
to grade 1 at the 2-month follow-up visit.
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EBT with surface applicators does have a distinct beam
flatness profile where nearly 100% of the dose encom-
passes the entire diameter of the surface applicator (Fig-
ure 3). This dosimetric advantage could potentially lead
to reduced margin requirements for the treatment of
cutaneous malignancies due to lack of penumbra [17-20].
Typically, at our institution, a 5 mm margin is utilized
for these patients undergoing EBT using surface applica-
tors. However, there are certain locations such as nasal
tip, nasal ala, and facial areas near the eye, where a 5 mm
margin is not feasible or desirable. Therefore, a reduced
margin was utilized to account for these critical anatomic
locations. A reduced treatment margin also could result
in minimal toxicities with small treatment volumes com-
pared to treating larger volumes as may be needed for
other radiation modalities. These properties of EBT with
surface applicators could lead to this modality becoming
an acceptable treatment option for patients with NMSC.
Conclusions
The early outcomes of electronic brachytherapy for the
treatment of NMSC show acceptable acute toxicity and
favorable early cosmesis. The hypofractionated approach
provides patient convenience with effective early out-
comes. Long-term follow up is in progress to further
assess efficacy and cosmesis.
Additional Information
This study will be presented at the 2010 Annual Meet-
ing of the American Society for Therapeutic Radiology
and Oncology in San Diego, CA.
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